CompanyYARWNasdaqNew Haven, CT

Yarrow Bioscience, Inc.

Yarrow Bioscience develops YB-101, an anti-TSHR monoclonal antibody for Graves' disease and thyroid eye disease.

SEC EDGAR ClinicalTrials.gov yarrowbioscience.com

424B5Sep 28Latest SEC filing

Sep 14Latest story

September 2026

Yarrow Bioscience prices $161.8M stock offering, expected to close Sept 14

Sep 14PartnershipYarrow Bioscience, Inc.

August 2026

Yarrow Bioscience files amended 8-K with Pre-Merger Yarrow financials after VYNE merger

Aug 13Quarterly updateYarrow Bioscience, Inc.

July 2026

Yarrow Bioscience details Phase 2a/2b trial design, merger share counts after VYNE closing

Jul 28Clinical readoutYarrow Bioscience, Inc.

VYNE approves 1-for-50 reverse split, sets special dividend ahead of Yarrow merger

Jul 21Regulatory decisionYarrow Bioscience, Inc.

VYNE declares special dividend tied to pending Yarrow Bioscience merger

Jul 10M&AYarrow Bioscience, Inc.

Yarrow Bioscience registers Phase 2 trial of YB-101 in Graves' Disease

Jul 6Trial updateYarrow Bioscience, Inc.